Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

Centre Hospitalier Universitaire de Nīmes174 enrolled

Overview

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return of the patient to his home.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

174

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Pharmaceutical consultation at the hospitalOTHER

During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.

Pharmaceutical consultation at the pharmacyOTHER

During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.

Follow-up pharmaceutical consultation at the pharmacyOTHER

During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient has signed the consent form. * The patient is affiliated to a health insurance programme * The patient is at least 18 years old (≥). * The patient is admitted to complete hospitalization (for patients in the "Hospital and Control" groups). * The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility. * The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease. * The patient returns to his / her home when discharged from hospital (for patients in the "Hospital and Control" groups). * The patient is available for a follow-up of 12 months. Exclusion Criteria: * The subject participates in another interventional study. * The subject is in an exclusion period determined by a previous study. * The patient is under safeguard of justice. * The subject refuses to sign the consent. * It is not possible to give the patient (or his/her trusted-person) informed information.

Locations (1)

Nimes University Hospital

Nîmes, France

Outcomes

Primary Outcomes

Number of exacerbation events

Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.

Time frame: Month 3

Number of exacerbation events

Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.

Time frame: Month 6

Number of exacerbation events

Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.

Time frame: Month 9

Number of exacerbation events

Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.

Time frame: Month 12

Secondary Outcomes

Number of visits to the attending physician

Time frame: Month 3

Number of visits to the attending physician

Time frame: Month 6

Number of visits to the attending physician

Time frame: Month 9

Number of visits to the attending physician

Time frame: Month 12

Number of visits to the pulmonologist

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.